Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 114-118

  Bernard, Mélisande ^a   Brignone, Mélanie ^b   Adehossi, Alain ^c   Pefoura, Samuel ^d   Briquet, Caroline ^d   Chouaid, Christos ^b,e   Tilleul, Patrick ^b,f  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Centre Hospitalier de Beauvais   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Alopecia; Chemotherapy; Lung cancer; Quality of life; Willingness to pay

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ALOPECIA; ARTICLE; ATTITUDE TO HEALTH; CANCER CHEMOTHERAPY; CORRELATION ANALYSIS; EDUCATIONAL STATUS; FEMALE; HAIR LOSS; HUMAN; INCOME; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTICENTER STUDY; OCCUPATION; PERCEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; VISUAL ANALOG SCALE;

ALOPECIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERCEPTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 79952191616     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.004     Document Type: Article

References (26)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Boyle P. Favourable trends in cancer mortality in the European Union but no room for complacency. Ann Oncol 2008, 19:605-606.
3. Lemieux J., Maunsell E., Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology 2008, 17:317-328.
4. Carpenter J.S., Brockopp D.Y. Evaluation of self-esteem of women with cancer receiving chemotherapy. Oncol Nurs Forum 1994, 21:751-757.
5. Noh D.Y., Nam S.J., Ahn S.H., Park B.W., Lee E.S., Lee M.K., Kim S.H., Kim Y.M., Park S.M., Yun Y.H. Association of clinical experiences with patient-reported outcomes among breast cancer surgery patients: breast cancer quality care study. Qual Life Res 2008, 17:215-225.
6. Girgis A., Breen S., Stacey F., Lecathelinais C. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. J Clin Oncol 2009, 27:6180-6190.
7. Helbekkmo N., Strøm H.H., Sundstrøm S.H., Aasebø U., Von Plessen C., Bremnes R.M. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol 2009, 48:1019-1025. Norwegian Lung Cancer Study Group.
8. Manser R.L., Wright G., Byrnes G., Hart D., Conron M., Carter R., McLachlan S.A., Campbell D.A. Validity of the assessment of quality of life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer 2006, 53:217-229.
9. Munstedt K., Manthey N., Sachsse S., Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997, 5:139-143.
10. Carelle N., Piotto E., Bellanger A., Germanaud J., Thuillier A., Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002, 95:155-163.
11. McGarvey E.L., Baum L.D., Pinkerton R.C., Rogers L.M. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001, 9:283-289.
12. Hesketh P.J., Batchelor D., Golant M., Lyman G.H., Rhodes N., Yardley D. Chemotherapy-induced alopecia: psychological impact and therapeutic approaches. Support Care Cancer 2004, 12:543-549.
13. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar, Manegold C., Paul S., Paoletti P., Einhorn L., Bunn P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
14. Potière C., Moatti J.P., Maraninchi D., Viens P. Choice and elicitation of preferences, toward therapeutic decision sharing in cancerology: from economic theory to medical practice. Bull Cancer 1998, 85:173-179.
15. Aristides M., Chen J., Schulz M., Williamson E., Clarke S., Grant K. Conjoint analysis of a new chemotherapy: willingness to pay and preference for features of raltitrexed versus standard therapy in advances colorectal cancer. Pharmacoeconomics 2002, 20:775-784.
16. Gafni A. Willingness to pay: what's in name. Pharmacoeconomics 1998, 14:465-470.
17. Olsen J.A., Smith R.D. Theory versus practice: a review of " Willingness To Pay" in health and health care. Health Econ 2001, 10:39-52.
18. Franic D.M., Pathak D.S., Gafni A. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of survey. J Clin Epidemiol 2005, 58:291-303.
19. Morris J., Lecturer S. Willingness to pay for new chemotherapy for advanced ovarian cancer. N Z Med J 2000, 113:143-146.
20. Dranitsaris G., Elia-Pacitti J., Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 2004, 22:375-387.
21. Tan Sean P., Chouaid C., Hettler D., Baud M., Hejblum G., Tilleul P. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Curr Med Res Opin 2009, 25:1455-1460.
22. Brown A., Aristides M., FitzGerald P., Liepa A., Boyer M., Clarke S. Patient preference and willingness to pay for permetrexed versus docetaxel in the second line treatment of advanced non small cell lung cancer: a discrete choice conjoint analysis. ISPOR outcomes research digest, PCN7, 2nd Asia-Pacific conference 2006.
23. Leighl N.B., Tsao W.S., Zawisza D.L., Nematollahi M., Shepherd F.A. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006, 51:115-121.
24. Slevin M.L., Stubbs L., Plant H.J., Wilson P., Gregory W.M., Armes P.J., Downer S.M. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990, 300:1458-1460.
25. Yasunaga H., Ide H., Imamura T., Ohe K. The measurement of willingness to pay for mass cancer screening with whole-body PET (positron emission tomography). Ann Nucl Med 2006, 20:457-462.
26. Dranitsaris G., Leung P., Ciotti R., Ortega A., Spinthouri M., Liaropoulos L., Labianca R., Quadri A. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics 2001, 19:955-967.